Cryptocurrency & Digital Assets

A new report challenges raid-focused tactics, using survivor stories to offer a blueprint for preventing exploitation in America's illicit massage industry.

A new study on a compact, wireless robotic device could democratize access to precision knee surgery, thanks to pioneering work from a rural Missouri surgeon.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

Cybersecurity firm Corero appoints an award-winning leader to supercharge its partner program, signaling a major push in the competitive DDoS defense market.

Challenger brand Kodiak partners with analytics giant NIQ, signaling a new data-driven era for competition in the crowded CPG breakfast and snacking aisles.

With major backing from Goldman Sachs, a biotech firm is advancing a potentially life-changing gene therapy for a rare, progressive form of blindness.

Westwater Resources heads to a key investor conference, carrying the weight of its Alabama graphite projects and the future of America's EV supply chain.

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.

The software giant is launching AI-powered AP automation, mobile payments, and integrated financing to tackle contractor cash flow and operational headaches.

The NBA partners with broker STARTRADER in a multi-year deal, signaling a major push into the Middle East and a new playbook for FinTech branding.

A $10 billion fund. Two competing visions. Wingspan Advisors' unique 'Alpha Summit' will decide the future of its ambitious new investment vehicle.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

At CES 2026, LumiMind's BCI tech promises to guide you to sleep and power thought-controlled games, raising major scientific and ethical questions.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

CES 2026: A new platform, Liquid Canvas, aims to liberate digital art from brand-locked TVs, offering a universal subscription for any screen.

South Korean gim specialist Daingt is leveraging proprietary data and a 20-year legacy to innovate its seaweed, aiming to dominate the booming global market.

Chase will become the new issuer for Apple Card, inheriting a $20B portfolio in a move that signals a major shift in the digital finance landscape.

Webull's new Vega AI offers institutional-grade analysis at no cost, shaking up the competitive brokerage market and raising questions for regulators.